Ostrum Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Ostrum Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$441K	Sell	3,344 -982	-23%	-$130K	0.02%	335
2025 Q4	$614K	Sell	4,326 -1,433	-25%	-$208K	0.03%	358
2025 Q3	$808K	Sell	5,759 -352	-6%	-$47.7K	0.04%	347
2025 Q2	$768K	Sell	6,111 -175	-3%	-$20.1K	0.04%	348
2025 Q1	$695K	Sell	6,286 -4,917	-44%	-$623K	0.04%	362
2024 Q4	$1.53M	Sell	11,203 -8,439	-43%	-$1.04M	0.13%	242
2024 Q3	$2.26M	Buy	19,642 +239	+1%	+$32.8K	0.19%	196
2024 Q2	$2.67M	Sell	19,403 -1,508	-7%	-$207K	0.23%	141
2024 Q1	$2.88M	Hold	20,911	–	–	0.23%	136
2023 Q4	$2.76M	Sell	20,911 -8,225	-28%	-$947K	0.24%	135
2023 Q3	$3.28M	Buy	29,136 +3,028	+12%	+$319K	0.3%	81
2023 Q2	$2.46M	Buy	26,108 +23	+0.1%	+$2.25K	0.21%	164
2023 Q1	$2.64M	Buy	+26,085	New	+$2.71M	0.23%	149

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ostrum Asset Management's NBIX Position: Q1 2026 in Review

Ostrum Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 23% in Q1 2026, selling an estimated $130K and leaving 3,344 shares worth $441K. The position accounts for 0.02% of the portfolio, ranked #335.

Ostrum Asset Management first reported a position in NBIX in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.28M in Q3 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Ostrum Asset Management held 3,344 shares of Neurocrine Biosciences worth $441K as of Q1 2026.
Ostrum Asset Management sold 982 Neurocrine Biosciences shares in Q1 2026, an estimated $130K.
Neurocrine Biosciences made up 0.02% of Ostrum Asset Management's portfolio in Q1 2026, its #335 holding.
Ostrum Asset Management first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 13 quarters since.
Ostrum Asset Management's Neurocrine Biosciences position peaked at $3.28M in Q3 2023.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Ostrum Asset Management's 13F filing for Q1 2026, filed 14 May 2026.